www.hhs.gov U.S. Department of Health and Human Services
Activity Outline
FDA Grand Rounds: A Pandemic and a Call to Action for One Health: The FDA One Health Initiative
June 11, 2020
Webcast
Activity Coordinator:
Devin Thomas (Devin.Thomas@fda.hhs.gov),  Jeff Rexrode (Jeffery.Rexrode@fda.hhs.gov)
 
Series Description

The FDA Grand Rounds is webcast every other month to highlight cutting-edge research underway across the agency and its impact on protecting and advancing public health. Each session features an FDA scientist presenting on a key public health challenge and how FDA is applying science to its regulatory activities.


Lecture Description
The Food and Drug Administration (FDA) is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and by ensuring the safety of our nation's food supply, cosmetics, and products that emit radiation. There are many factors that pose risks or threaten public health. FDA's efforts to improve health goes beyond recognizing disease transmission in an isolated lens of human health, but also acknowledges human-animal interactions and associated environmental factors such as socioeconomic status, behavior, and other social determinants. Addressing human and animal intersectoral factors that are both biological and environmental is a complex endeavor requiring a great deal of knowledge, skills, and resources from various disciplines. However, as health disciplines become progressively specialized, they also become more siloed. One Health is a concept that embraces a multisectoral and transdisciplinary approach to solving health problems by recognizing the interconnection between humans, animals, and their shared environment. Many global changes and activities associated with increased human-animal interactions are enabling disease transmission that become epidemics or pandemics that adversely impact public health. This presentation will explain the One Health Concept and the FDA One Health Initiative. It will also highlight the benefits of One Health and how FDA is operationalizing One Health actions agency wide.
References
  • Will COVID-19 generate global preparedness? https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30559-6/fulltext
  • World Bank’s One Health Framework: Operational framework for strengthening human, animal and environmental public health systems at their interface. http://documents.worldbank.org/curated/en/703711517234402168/Operational-framework-for-strengthening -human-animal-and-environmental-public-health-systems-at-their-interface
  • The Need for National Strategy to Address Vector-Borne Disease Threats in the United States. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058377/
  • One Health AIDS to ZIka. https://www.youtube.com/watch?v=KXjXUMzsQ_s
  • One Health proof of concept: Bringing a transdisciplinary approach to surveillance for zoonotic viruses at the human-wild animal interface. https://www.ncbi.nlm.nih.gov/pubmed/28034593
  • The Three One Health Websites: 1.One Health Initiative Website: http://www.onehealthinitiative.com/mission.php 2. One Health Commission Website: https://www.onehealthcommission.org/ 3 One Health Platform website: http://onehealthplatform.com/
Series Objectives
  • Discuss the research conducted at the FDA
  • Explain how FDA science impacts public health
Learning Objectives After completion of this activity, the participant will be able to:
  • Explain the mission and goals of the FDA One Health Initiative.
  • Identify recent FDA One Health Initiative related activities.
  • Discuss why a One Health approach to pandemics is the new norm.
Target Audience
This activity is intended for physicians, pharmacists, nurses, and other scientists within the agency external scientific communities.
Agenda

Lecture 1 June 11, 2020
Time Topic Speaker
12:00 - 1:00 PM A Pandemic and a Call to Action for One Health: The FDA One Health Initiative Brianna Skinner, DVM
Bernadette Dunham, DVM, Ph.D.
Continuing Education Accreditation
Jointly Accredited Provider
In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ICPE Credit
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
CME
FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE
This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-20-022-L04-P for 1.00 contact hour(s).
CNE
FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).
Requirements for Receiving CE Credit

Physicians, pharmacists, nurses, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.

Pharmacists will need their NABP e-profile ID number as well as their DOB in MMDD format in order to claim CE credit.

Important Note regarding completion of evaluations and receiving credit
Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit.Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 10 weeks after the last session of the activity to obtain their CE credit.
Disclosure

Faculty
  • Dunham, DVM, Ph.D., Bernadette, Professorial Lecturer, The George Washington University - nothing to disclose
  • Skinner, Brianna, DVM, Chief Regulatory Veterinarian, Office of Counter-Terrorism & Emerging Threats - nothing to disclose

Planning Committee
  • Dinatale, Miriam, Team Leader, Food and Drug Administration - nothing to disclose
  • Pfundt, Tiffany, PharmD, Pharmacist, FDA - nothing to disclose
  • Thomas, Devin, LCDR, MPH, CHES, Health Promotions Specialist, FDA/OC/OCS/OSPD - nothing to disclose
  • Wheelock, Leslie, RN, MS, RN, Director, OSPD, FDA, OC, OCS, OSPD - nothing to disclose

CE Consultation and Accreditation Team
  • Bryant, Traci, M.A.T., CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose
  • Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose
Registration Fee and Refunds
Registration is complimentary, therefore refunds are not applicable.
ACCME Joint Accreditation
  • This warning banner provides privacy and security notices consistent with applicable federal laws, directives, and other federal guidance for accessing this Government system, which includes (1) this computer network, (2) all computers connected to this network, and (3) all devices and storage media attached to this network or to a computer on this network.
  • This system is provided for Government-authorized use only.
  • Unauthorized or improper use of this system is prohibited and may result in disciplinary action and/or civil and criminal penalties.
  • Personal use of social media and networking sites on this system is limited as to not interfere with official work duties and is subject to monitoring.
  • By using this system, you understand and consent to the following:
    • The Government may monitor, record, and audit your system usage, including usage of personal devices and email systems for official duties or to conduct HHS business. Therefore, you have no reasonable expectation of privacy regarding any communication or data transiting or stored on this system. At any time, and for any lawful Government purpose, the government may monitor, intercept, and search and seize any communication or data transiting or stored on this system.
    • Any communication or data transiting or stored on this system may be disclosed or used for any lawful Government purpose.